Protagonist Therapeutics (PTGX) is a relatively unknown biotech company focused on the development of novel peptide drugs. The company has recently shown exciting data for their hepcidin mimetic drug PTG-300 in Polycythemia Vera ("PV") which resulted in a doubling of their share price. In this article, I will outline why I believe the market has still not fully appreciated the opportunity of this drug in PV, nor has it properly valued the possibilities for this product in Hereditary Hemochromatosis ("HH"). The company has two other pipeline products that, while earlier stage, each bolster the investment